Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evofem Biosciences, Inc. (EVFM)
|
Add to portfolio |
|
|
|
| Price: |
$1.92
| | Metrics |
| OS: |
4.06
|
M
| |
|
|
| Market cap: |
$7.79
|
M
| |
|
|
|
Net debt:
|
$15.6
|
M
| |
|
|
|
EV:
|
$23.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($40.8)
|
M
| |
|
|
|
EBIT
|
($41.7)
|
M
| |
|
|
| EPS |
($7.32)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 16.8 | 8.2 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 104.2% | 1748.4% | | | | | | |
| Cost of goods sold | 4.4 | 4.1 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 12.4 | 4.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 73.8% | 50.8% | -4.9% | | | | | |
| Sales and marketing | 44.0 | 113.2 | 56.5 | 10.2 | | | | |
| Research and development | 25.0 | 33.1 | 17.1 | 22.2 | 43.4 | 23.5 | 6.6 | 34.4 |
| General and administrative | 27.6 | 24.7 | 30.1 | 20.3 | 34.2 | 12.1 | 5.5 | 7.6 |
| EBIT | -84.1 | -166.8 | -103.6 | -52.7 | -77.6 | -35.7 | -12.0 | -42.0 |
| EBIT margin | -499.6% | -2023.3% | -23234.1% | | | | | |
| Pre-tax income | -76.7 | -205.2 | -142.3 | -80.0 | -125.7 | -105.3 | -13.0 | -43.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | 0.0% | 0.0% |
| Net income | -78.0 | -206.2 | -142.3 | -80.0 | -125.8 | -109.3 | -13.0 | -43.2 |
| Net margin | -463.3% | -2501.7% | -31907.8% | | | | | |
| |
| Diluted EPS | ($1.34) | ($23.63) | ($2.12) | ($1.99) | ($5.74) | ($55.78) | ($5.66) | ($18.91) |
| Shares outstanding (diluted) | 58.2 | 8.7 | 67.2 | 40.2 | 21.9 | 2.0 | 2.3 | 2.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|